Compare First Trust Cloud Computing ETF (SKYY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Viatris Inc — how do they compare? First Trust Cloud Computing ETF trades at $173.15 (market cap $3.47B), while Viatris Inc trades at $17.5 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 5.8× First Trust Cloud Computing ETF's market cap, and Viatris Inc pays a 2.75% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 84 Days and Viatris Inc for 57 Days on average.
| SKYY | VTRS | |
|---|---|---|
Market Cap | $3.47B | $20.03B |
Volume | 176,159 | 14,109,977 |
52-Week High | $171.01 | $18.27 |
52-Week Low | $104.16 | $9.74 |
Typical Hold Time | 84 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY (First Trust Cloud Computing ETF) trades at $171.75, up 0.57% today and recently hitting a new 52-week high. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF benefits from strong secular trends in cloud computing and AI infrastructure spending, with recent news highlighting institutional position adjustments and positive sector outlook.
The outlook remains positive given cloud computing's growth trajectory and AI-driven demand, though valuation metrics are unavailable for analysis. Risks include sector concentration and market volatility. Institutional activity shows mixed signals with some trimming positions while sector analysts maintain optimistic coverage on cloud computing infrastructure growth.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
